On the other hand, there are also non-steroidal MR compounds, which do not have gynecomastia as an adverse effect, with a high affinity (greater than spironolactone and eplerenone) for the mineralocorticoid receptor. This evidence concerns the gene NR3C2 and Gynecomastia.